.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
ZeroHarm Sciences recently raised Rs 65 crore to scale its innovative plant-based nutraceutical brand. Consequently, this capital infusion from Kotak Life Sciences Fund and Alkemi Growth Capital marks a major milestone. The company intends to enhance its research capabilities and global reach.
Specifically, ZeroHarm uses proprietary nano-formulation technology to increase the bioavailability of its supplements. This method ensures that herbal actives are absorbed more effectively by the body. Furthermore, the firm is building India's first \"Trust over Promise\" health platform. This model correlates supplement use with measurable diagnostic results.
Additionally, the startup plans to enter markets in the US, UK, and the Middle East. ZeroHarm maintains a vertically integrated ecosystem, covering extraction, R&D, and manufacturing. Notably, this structure allows for strict quality control and standardized health outcomes. Because of these factors, investors see high potential in the company’s science-led approach.
Q1: What is the \"Trust over Promise\" platform?
The \"Trust over Promise\" platform allows customers to see measurable health outcomes through before-and-after diagnostic testing.
Q2: How does nano-formulation technology benefit patients?
Nano-formulation breaks down herbal actives into ultra-fine particles, which significantly improves their absorption and efficacy compared to traditional supplements.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
ZeroHarm Sciences raised Rs 65 crore to expand its plant-based nutraceutical brand using nano-technology and a diagnostic-led health outcome model....
4 months ago
A community survey in Blantyre, Malawi, shows that sex differences in tuberculosis immunoreactivity emerge during early adulthood, peaking at age 21 with 1.58-fold higher conversion risk in males. Tobacco and alcohol use drive community transmission, highlighting the need for targeted active case finding.
Today
A prospective study from the Barcelona Life Study Cohort shows that prenatal air pollution exposure is associated with increased placental mitochondrial DNA content, reflecting compensatory biogenesis. No significant changes were found in telomere length, and neither biomarker directly mediated birth weight.
Today
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
Today
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
Today
A parliamentary standing committee has directed FSSAI to expedite front-of-pack nutrition labelling regulations. The panel highlighted that over two years of delay since the 2022 draft notification leaves consumers relying on complex numerical labels, urging simple color-coded sugar indicators and warnings.
Today
